46brooklyn Research

09/14/2026

“340B becomes an all-you-can-eat buffet of opportunities for vertically integrated companies.”

Hospitals are filing more lawsuits against CVS Health, alleging the company withheld 340B drug payments from safety-net providers.

08/21/2026

“In the era of managed care, fraud, waste and abuse prevention has to extend far beyond the provider level because providers can engage in small-scale fraud.

But now that insurance companies and their vertically integrated subsidiaries stand in between the provider and the state paying the bill, vertical integration has created conflicts of interest and opportunities for fraud, waste and abuse to be conducted at a far larger scale.”

The Trump administration and Ohio Republicans say they're fighting Medicaid fraud. But they never mentioned corporate contractors.

08/16/2026

“You cannot make a good decision — in any direction — with a ruler that doesn't measure what you think it measures.”

CPI says health insurance costs fell 8% and drug prices 3.1% in 2026. Neither measures what you pay. We recalculated core inflation with real premium data.

08/01/2026

"Be very clear about what definitions are in your contract."

Too often, Ben Link says, the plan's actual value depends on what the PBM does to the parameters.

07/21/2026

Love seeing our research featured in the Senate Finance Committee minority staff roadmap for lowering prescription drug prices

https://www.finance.senate.gov/imo/media/doc/061626_sfc_drug_pricing_rfi.pdf

07/14/2026

Everyone thinks generic competition equals lower prices. The data says otherwise.

When PBMs classify cheap generic cancer drugs as "specialty," natural price erosion vanishes, turning $100 medications into $2,700+ pharmacy bills.

Our latest deep-dive unpacks the structural flaws backing the CBO's recent $500B Medicare Part D spending panic, using Abiraterone and Lenalidomide as case studies in how the drug channel hides the true cost of generics. 📈👇

In late 2025, the Congressional Budget Office (CBO) issued an unusual request – a call for new research into Medicare Part D spending. The request stemmed from CBO’s own observations regarding Part D spending, which showed that federal spending on the Medicare Part D benefit, which covers prescr...

07/09/2026

“The results were that plans preferred brands over generics, patients paid more out-of-pocket, and federal reinsurance costs exploded.”

05/20/2026

TrumpRx expands its cash-pay medication footprint significantly through alliances with Amazon, GoodRx, and Mark Cuban

The White House’s drug pricing initiative will now feature generics, relying on Cost Plus Drugs and other drug discount companies.

05/16/2026

Americans' voracious appetite for GLP-1 weight loss drugs has the nation on pace to spend more than $1 trillion on prescription drugs this year.

05/12/2026

“This is not a material change, it’s business as usual.”

For all of President Donald Trump’s showmanship, the share of Americans his policies will likely help remains slim, even if some patients do come out ahead.